Tonix Pharmaceuticals has reported positive results from a Phase ll, dose-finding clinical trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to treat military-related post-traumatic stress disorder (PTSD).

PTSD affects around 8.4 million Americans in any year and can develop from witnessing or experiencing a traumatic event, in which there was the severe threat or actual occurrence of grave physical harm.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase ll trial, AtEase Study, was a randomised, placebo-controlled study that included 231 patients with PTSD.

Conducted at 24 clinical sites in the US, the trial compared a bedtime sublingual dose of 2.8mg TNX-102 SL or 5.6mg TNX-102 SL with placebo to treat military-related PTSD.

"Conducted at 24 clinical sites in the US, the trial compared a bedtime sublingual dose of 2.8mg TNX-102 SL or 5.6mg TNX-102 SL with placebo to treat military-related PTSD."

The retention rates were reported to be 79% on TNX-102 SL 2.8mg, 84% on TNX-102 SL 5.6mg, and 73% on placebo.

The trials’ primary efficacy endpoint was the 12-week mean change from baseline in the severity of PTSD symptoms as measured by the clinician-administered PTSD Scale for DSM-5 (CAPS-5), between those treated with TNX-102 SL 2.8mg and those receiving placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tonix noted that the CAPS-5 is a standardised, structured clinical interview and serves as the gold standard in research to assess the symptom severity of PTSD.

The company’s investigational drug TNX-102 SL is waiting to be approved for indication and designed to deliver cyclobenzaprine to the bloodstream rapidly through sublingual (under the tongue) absorption, as well as bypass first-pass hepatic metabolism.

As a multifunctional agent with adversary activities at the serotonin-2A, alpha-1 adrenergic, and histamine H1 receptors, TNX-102 SL is currently under clinical development to treat PTSD and is expected to provide a broad range of improvement by targeting sleep and hyperarousal.

Tonix is developing TNX-102 SL 2.8mg for daily bedtime administration to treat fibromyalgia and TNX-102 SL 5.6mg for daily bedtime administration to treat PTSD.